On Friday, Prime Medicine Inc (NASDAQ: PRME) opened higher 9.44% from the last session, before settling in for the closing price of $2.60. Price fluctuations for PRME have ranged from $2.25 to $9.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -25.00% over the past five years. Company’s average yearly earnings per share was noted 26.60% at the time writing. With a float of $50.84 million, this company’s outstanding shares have now reached $131.16 million.
Let’s look at the performance matrix of the company that is accounted for 234 employees. In terms of profitability, gross margin is 98.47%, operating margin of -586.63%, and the pretax margin is -568.39%.
Prime Medicine Inc (PRME) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Prime Medicine Inc is 61.22%, while institutional ownership is 31.01%.
Prime Medicine Inc (PRME) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 26.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.17% during the next five years compared to -193.88% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Check out the current performance indicators for Prime Medicine Inc (PRME). In the past quarter, the stock posted a quick ratio of 6.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 465.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.01, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Prime Medicine Inc (NASDAQ: PRME) saw its 5-day average volume 1.12 million, a positive change from its year-to-date volume of 0.92 million. As of the previous 9 days, the stock’s Stochastic %D was 67.15%. Additionally, its Average True Range was 0.22.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 21.30%, which indicates a significant decrease from 73.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.78% in the past 14 days, which was higher than the 82.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.90, while its 200-day Moving Average is $4.38. Nevertheless, the first resistance level for the watch stands at $2.94 in the near term. At $3.04, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.18. If the price goes on to break the first support level at $2.70, it is likely to go to the next support level at $2.56. Assuming the price breaks the second support level, the third support level stands at $2.46.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
There are currently 131,161K shares outstanding in the company with a market cap of 372.49 million. Presently, the company’s annual sales total 0 K according to its annual income of -198,130 K. Last quarter, the company’s sales amounted to 210 K and its income totaled -52,520 K.
